Ann: Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea, page-98

You may be right on the wording.

I looked at what Polynovo were spending a while back as a guide, they also started a US sales team from scratch, though i acknowledge in quite a different health segment. I lost my notes but think it was circa $30m a year.

I also looked at Journey, the owners of Qbrexa.

Selling, general and administrative at $40m USD.

So taking on Qbrexa lead to an increase of $17.7m mostly attributed to Sales and Marketing, given they already had a base to build off I think $30m first year for BOT isnt unrealistic.

People hate the meer mention of a CR but it's a necessity and in the scheme of things if they're able to get any level of profit out of SB the dilution will be totally meaningless in the end.

Then again maybe we don't need to spend much to outsmart Journey given they lost $9,500,000 to an email scam last year!!